Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistanceResearch in context

Summary: Background: Nirmatrelvir-ritonavir (Paxlovid) and ensitrelvir are 3-chymotrypsin-like cysteine protease (3CLpro) inhibitors which have been approved for the treatment of COVID-19 in 2021 and 2022, respectively. Previous studies have identified 3CLpro mutations that are associated with redu...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jonathan Daniel Ip, Allen Wing-Ho Chu, Wan-Mui Chan, Rhoda Cheuk-Ying Leung, Syed Muhammad Umer Abdullah, Yanni Sun, Kelvin Kai-Wang To
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2023-05-01
Col·lecció:	EBioMedicine
Matèries:	COVID-19 SARS-CoV-2 Antiviral resistance Nirmatrelvir Ensitrelvir Protease inhibitor
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S235239642300124X
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!